Pacific Biosciences
PACB
PACB
250 hedge funds and large institutions have $2B invested in Pacific Biosciences in 2022 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 92 increasing their positions, 70 reducing their positions, and 48 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
8% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 48
2% less funds holding
Funds holding: 256 → 250 (-6)
52% less capital invested
Capital invested by funds: $4.2B → $2B (-$2.2B)
Holders
250
Holding in Top 10
5
Calls
$21.1M
Puts
$15.5M
Top Buyers
| 1 | +$92.6M | |
| 2 | +$38.3M | |
| 3 | +$31.1M | |
| 4 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
+$30.6M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$24.2M |
Top Sellers
| 1 | -$112M | |
| 2 | -$72.2M | |
| 3 | -$35.5M | |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$28.5M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$17.6M |